Liposomes as carriers of radionuclides: From imaging to therapy

Journal of Liposome Research

Volumn 9, Issue 4, 1999, Pages 429-460

  Kostarelos, K ^a   Emfietzoglou, D ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; RADIOISOTOPE;

CYTOTOXICITY; DIAGNOSTIC VALUE; DOSE RESPONSE; DOSIMETRY; DRUG HALF LIFE; DRUG TARGETING; IMAGE ANALYSIS; PARTICLE SIZE; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION;

EID: 0032760940     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.3109/08982109909035546     Document Type: Review

References (188)

1. Moghimi, S.M., Ilium, L., Davis, S.S. 1990. Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow. Crit Rev Ther Drug Carrier Syst 7(3):187-209.
2. Moghimi, S.M., Porter, C.J.H., Illum, L., Davis, S.S. 1991. The effect of poloxamer-407 on liposome stability and targeting to bone-marrow - comparison with polystyrene microspheres. Int J Pharm 68:121-126.
3. Bangham, A.D., Standish, M.M., Weismann, G. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238-252.
4. Gregoriadis, G., Buckland, R.A. 1973. Enzyme-containing liposomes alleviate a model for storage disease. Nature 254: 170-172.
5. Gregoriadis, G. 1973. Drug entrapment in liposomes. FEBS Lett 36:292-296.
6. Gregoriadis, G. (Ed.) Liposomes as drug carriers: recent trends and progress. John Wiley, Chichester, 1988.
7. Kirby, C., Clarke, J., Gregoriadis, G. 1980. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 186: 591-598.
8. Semple, S.C., Chonn, A., Cullis, P. R. 1996. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry 35:2521-2525.
9. Gregoriadis G., Senior, J.H. 1980. The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett 119:43-46.
10. Juliano, R., Stamp, D. 1975. Effects of particle size and charge on the clearance of liposomes and liposome-encapsulated drugs. Biochem Biophys Res Comm 63: 651-658.
11. Senior, J.H. 1987. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit Rev Ther Drug Carr Syst 3: 123-193.
12. Scherphof, G., Roerdink, D.G., Waite, M., Parks, J. 1978. Disintegration of phosphatidylcholine liposomes in plasma as a result of interactions with high density lipoproteins. Biochim Biophys Acta 542:296-307.
13. Moghimi, S.M., Patel, H.M. 1989. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochim Biophys Acta 984:384-387.
14. van Rooijen, N., Sanders, A. 1994. Liposome-mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Meth 174:83-93.
15. Lasic, D.D., Frederik, P.M., Stuart, M.C.A., Barenholz, Y., McIntosh, T.J. 1992. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 312:255-258.
16. Goldenberg, D.M. 1993. Monoclonal antibodies in cancer detection and therapy. Am J Med 94:297-312.
17. Kohler, G., Milstein, C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
18. Wilder, R. B., DeNardo, G. L., DeNardo, S. J. 1996. Radioimmunotherapy: Recent Results and future directions. J Clin Oncol 14:1383-1400.
19. Zaccolo, M., Malavasi, F. 1993. From cells to genes: how to make antibodies useful in human diagnosis and therapy. Int J Clin Lab Res 23(4):192-198.
20. Buchsbaum, D. J. 1995. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res (Suppl.) 55:5729s-5732s.
21. Wahl, R.L. 1994. Experimental radioimmunotherapy. A brief overview. Cancer 73(3 Suppl):989-992.
22. Scroff, R.W., Foon, K.A., Beatty, S.M., Oldham, R.K., Morgan, A.C. 1985. Human anti-mouse immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 48:879-885.
23. Kairemo, K.J. 1996. Radioimmunotherapy of solid cancers: A review. Acta Oncol 35(3):343-355.
24. Leserman, L.D., Barbet, J., Kourilski, F., Weinstein, J.N. 1980. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288:602-604.
25. Matthay, K.K., Heath, T.D., Badger, C.C., Bernstein, I.D., Papahadjopoulos, D. 1986. Antibody-directed liposomes: comparison of various ligands for association, endocytosis, and drug delivery. Cancer Res 46:4904-4910.
26. 2 to vesicle surface. Science 210:539-541.
27. Vidal, M., Sainte-Marie, J., Philippot, J.R., Bienvenue, A. 1987. The influence of coupling transferrin to liposomes or minibeads on its uptake and fate in leukemic L2C cells. FEBS Lett 216:159-163.
28. Hara, T., Aramaki, Y., Takada, S., Koike, K., Tsuchiya, S. 1995. Receptor mediated transfer of Psc2cat DNA to mouse liver cells using asialofetuin labeled liposomes. Gene Ther 2:784-788.
29. Allen, T.M., Hansen, C.B., Stuart, D.D. 1998. Targeted sterically stabilized liposomal drug delivery. In: Lasic, D.D. and Papahadjopoulos, D. (eds) Medical applications of liposomes. Elsevier Science, Amsterdam pp. 297-323.
30. Weinstein, J.N., van Osdol, W. 1992. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res 52:2747-2751.
31. Wallingford, R.H., Williams, L.E. 1985. Is stability a key parameter in the accumulation of phospholipid vesicles in tumors? J Nucl Med 26:1180-1185.
32. Caride (ref.34) describes an interesting distinction between 'tissues of extravasation' and 'tissues of restriction', based primarily on the anatomy of a major obstacle to the movement of liposomes into the extravascular space, the capillary wall. 'Tissues of restriction' have continuous capillaries, tightly sealed by junctions between endothelial cells, and a continuous basement membrane. On the other hand he defines 'tissues of extravasation' as having sinusoidal capillaries with larger fenestrations and absent or incomplete basement membrane.
33. Caride, V.J. 1990. Technical and biological considerations on use of radiolabeled liposomes for diagnostic imaging. Nucl Med Biol 17(1):35-39.
34. Caride, V.J., Zanet, B.L. 1977. Liposome accumulation in regions of experimental myocardial infarction. Science 198:735-738.
35. Palmer, T.N., Caride, V.J., Caldecourt, M.A., Twickler, J., Abdullah, V. 1984. The mechanism of liposome accumulation in infarction. Biochim Biophys Acta 797: 363-368.
36. Proffitt, R.T., Williams, L.E., Presant, C.A., Tin, G.W., Uliana, J.A., Gamble, R.C., Baldeschwieler, J.D. 1983. Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. J Nucl Med 24(1):45-51.
37. 67Ga-carrying liposomes. Eur J Nucl Med 11:405-411.
38. 99mTc-labelled liposomes in patients with cancer. Cancer Res 44:375-378.
39. Presant, C.A., Proffitt, R.T., Turner, A.F., Winsor, D., Werner, J.L., Williams, L.E., Kennedy, P., Wiseman, C., Gala, K., McKenna, R.J., Smith, J.D., Sakulsky, S.B., Bouzaglou A., Callahan, R.A., Baldeschwieler, J., Crossley, R.J. 1988. Successful imaging of human cancer with radiolabeled phospholipid vesicles (liposomes). Cancer 62:905-911.
40. Presant, C.A., Turner, A.F., Proffitt, R.T. 1994. Potential for improvement in clinical decision-making: tumor imaging with In-111 labeled liposomes results of a Phase II-III study. J Liposome Res 4(2):985-1008.
41. Woodle, M.C., Collins, L.R., Sponsler, E., Kossovsky, N., Papahadjopoulos, D., Martin, F.J. 1992. Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential. Biophys J 61:902-910.
42. Mauk, M.R., Gamble, R.C., Baldeschwieler, J.D. 1980. Targeting of lipid vesicles: specificity of carbohydrate receptor analogues for leukocytes in mice. Proc Natl Acad Sci U S A 77(8):4430-4434.
43. Allen, T. M., Chonn, A. 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223:42-46.
44. Klibanov, A.L., Maruyama, K., Torchilin, V.P., Huang, L. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235-237.
45. Blume, G., Cevc, G. 1990. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1029:91-97.
46. Senior, J., Delgado, C., Fisher, D., Tilcock, C., Gregoriadis, G. 1991. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062:77-82.
47. Phillips W.T., Goins, B. 1995. Targeted delivery of imaging agents by liposomes. In: Torchilin, V.P. (ed) 1995. Handbook of targeted delivery of imaging agents. CRC Press, Boca Raton, FL pp. 149-173.
48. 11In to image focal infection in rats. J Nucl Med 36:1639-1644.
49. Turner, J.E. Atoms, radiation, and radiation protection. Wiley, New York, 1995.
50. Chandra, R. Introductory physics of nuclear medicine. Lea & Febiger, Philadelphia, Pennsylvania, 1992.
51. Mausner, L.F., Srivastava, S. C. 1993. Selection of radionuclides for radioimmunotherapy. Med Phys 20:503-509.
52. Zweit, J. 1996. Radionuclide and carrier molecules for therapy. Phys Med Biol 41: 1905-1914.
53. Bushberg, J. T., Seibert, J. A., Leidholdt, E. M., Boone, J. M. The essential physics of medical imaging. Williams & Wilkins, Baltimore, Maryland, 1994.
54. Ott, R.J. 1996. Imaging technologies for radionuclide dosimetry. Phys Med Biol 41:1885-1894.
55. Seltzer S.E. 1988. Liposomes in diagnostic imaging. In: Gregoriadis G. (ed) Liposomes as drug carriers: recent trends and progress. John Wiley & Sons, Chichester, pp.509-525.
56. Seltzer S.E. 1989. The role of liposomes in diagnostic imaging. Radiology 171: 19-21.
57. Torchilin, V.P., Trubetskoy, V.S. 1995. In vivo visualizing of organs and tissues with liposomes. J Liposome Res 5:795-812.
58. Tilcock, C. 1995. Imaging tools: liposomal agents for nuclear medicine, computed tomography, magnetic resonance, and ultrasound. In: Philippot, J.R., Schuber, F. (eds) Liposomes as tools in basic research and industry. CRC Press, Boca Raton, FL, pp. 225-240.
59. Seltzer, S.E., Davis, M.A., Adams, D.F., Shulkin, P.M., Landis, W.J., Havron, A. 1984. Lipsomes carrying diatrazoate: characterization of biophysical properties and imaging applications. Invest Radiol 19:142-151.
60. Caride, V.J., Sostman, H.D., Twickler, J., Zacharis, H., Urphanoukis, S.C., Jaffe, C.C. 1984. Brominated radiopaque liposomes: contrast agent for computed tomography of liver and spleen. A preliminary report. Invest Radiol 17:381-385.
61. Janoff, A.S., Minchey, S.R., Perkins, W.R., Boni, L.T., Seltzer, S.E., Adams, D.F., Blau, M. 1991. Interdigitation fusion vesicles: a new approach to selective opacification of the RES. Invest Radiol 26(suppl): S167-169.
62. Sachse A., Leike J.U., Schneider T, Wagner S.E., Robling GL, Krause W, Brandi M. Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes. Invest Radiol 1997: 32(1): 44-50.
63. Fouillet, V., Tournier, H., Khan, H., Saditha, S., Burkhardt, S., Terrier, F., Schneider, M. 1995. Enhancement of computed tomography liver contrast using iomeprol-containing liposomes and detection of small liver tumors in rats. Acad Radiol 2: 576-583.
64. Petersein, J., Franke, B., Fouillet, X., Hamm, B. 1999. Evaluation of liposomal contrast agents for liver CT in healthy rabbits. Invest Radiol 34(6):401-409.
65. Schmiedl, U., Krause, W., Leike, J., Nelson, J.A., Schuhmann-Giamprieri, G. 1995. Liver contrast enhancement in primates using iopromide liposomes. Acad Radiol 2:967-972.
66. Leander, P., Hoglund, P., Kloster, Y., Borseth, A. 1998. New liposomal liver-specific contrast agent for CT: first human Phase I clinical trial assessing efficacy and safety. Acad Radiol 5(suppl 1): S6-S8.
67. Hoglund, P., Leander, P., Hustvedt, S.O., Kloster, Y., Borseth, A. 1998. Human pharmacokinetics and modeling of the concentration-attenuation relationship of a new liposomal liver-specific contrast agent for CT. Acad Radiol 5(suppl 1): S47-S48.
68. Gupta, H., Weissleder, R. 1996. Targeted contrast agents in MRI imaging. MRI Clin N Am 4(1):171-184.
69. Torchilin, V.P. 1998. Liposomes as carriers of contrast agents for in vivo diagnostics. In: Lasic, D.D. and Papahadjopoulos, D. (eds) Medical applications of liposomes. Elsevier Science, Amsterdam pp.515-543.
70. Caride, V.J., Sostman, H.D., Winchell, R.J., Gore, J.C. 1984. Relaxation enhancement using liposomes carrying paramagnetic species. Magn Reson Imag 2:107-112.
71. Kabalka, G., Buonocore, E., Hubner, K., Davis, M., Huang, L. 1988. Gadolinium-labeled liposomes containing paramagnetic amphipathis agents: targeted MRI contrast agent for the liver. Magn Res Med 8:89-95.
72. Tilcock, C., Unger, E., Cullis, P.., MacDougall, P. 1989. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology 171:77-80.
73. Schwendener, R., Wurthrich, R., Duewell, S., Wehrli, E., von Schulthess, G.A. 1990. A pharmacokinetic and MRI study of unilamellar gadolinium-, maganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest Radiol 23:922-932.
74. Barsky, D., Putz, B., Schulten, K., Magin, R.L. 1992. Theory of paramagnetic contrast agents in liposome systems. Magn Reson Med 21:1-13.
75. Lasic, D. D. Liposomes: from physics to applications. Elsevier Science, Amsterdam, 1993.
76. Trubetskoy, V.S., Cannillo, J.A., Milshtein, A., Wolf, G.L. 1995. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. Magn Res Imag 13:31-37.
77. Unger, E., Winokur, T., MacDougall, P., Rosenblum, J., Clair, M., Gatenby, R., Tilcock, C. 1989. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology 171:81-85.
78. Grunter, W., Biesold, M., Wagner, M., Werner, A. 1998. Improved nuclear magnetic resonance microscopic visualization of joint cartilage using liposome entrapped contrast agents. Inv Radiol 33:193-202.
79. Tilcock, C., Liposomal blood pool agents for nuclear medicine and magnetic resonance imaging. J Liposome Res 4:909-936.
80. Bulte, J.W., de Cuyper, M., Despres, D., Frank, J.A. 1999. Short-vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents. J Magn Reson Imag 9(2):329-335.
81. Storrs, R.W., Tropper, F.D., Li, H.Y., Song, C.K., Sipkins, D.A., Kuniyoshi, J.K., Bednarski, M.D., Strauss, H.W., Li, K.C. 1995. Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J Magn Reson Imag 5(6):719-724.
82. 3-targeted magnetic resonance imaging. Nature Med 4(5):623-626.
83. Niesman, M.R., Khoobehi, B., Magin, R.L., Webb, A.G. 1994. Liposomes and diagnostic imaging: the potential to visualize both the structure and function. J Liposome Res 4:741-768.
84. Calvo, B.F., Semelka, R.C. 1999. Beyond anatomy: MR imaging as a molecular diagnostic tool. Surg Oncol Clin N Am 8(1):171-183.
85. Wisner, E.R., Aho-Sharon, K.L., Bennett, M.J., Penn, S.G., Lebrilla, C.B., Nantz, M.H. 1997. A modular lymphographic magnetic resonance imaging contrast agent: contrast enhancement with DNA transfection potential. J Med Chem 40:3992-3996.
86. Anghileri, L.J., Firusian, N., Brucksch, K.P. 1976. In vivo distribution of 99mTc-labeled liposomes. J Nucl Biol Med 1976 20(4):165-167.
87. Caride, V.J., Taylor, W., Cramer, J.A., Gottschalk, A. 1976. Evaluation of liposome-entrapped radioactive tracers as scanning agents. Part 1: Organ distribution of liposome (99mTc-DTPA) in mice. J Nucl Med 17(12):1067-1072.
88. Richardson, V.J., Jeyasingh, K., Jewkes, R.F., Ryman, B.E., Tattersall, M.H. 1977. Properties of [99mTc] technetium-labelled liposomes in normal and tumour-bearing rats. Biochem Soc Trans 5(1):290-291.
89. 99mTc-DTPA entrapped in multilamellar vesicles. J Nucl Med 20:434-440.
90. Morgan, JR, Williams, L.A., Howard, C.B. 1985. Technitium-labeled liposomes for deep-seated infection. Br J Radiol 58:35-39.
91. Love, W.G., Amos, N., Kellaway, I.W., Williams, B.D. 1989. Specific accumulation of technetium-99m radiolabelled, negative liposomes in the inflamed paws of rats with adjuvant induced arthritis: effect of liposome size. Ann Rheum Dis 48: 143-148.
92. Khalifa, A., Dodds, D., Rampling, R., Paterson, J., Murray, T. 1997. Liposomal distribution in malignant glioma: possibilities for therapy. Nucl Med Comm 18: 17-23.
93. Gabizon, A., Huberty, J., Straubinger, R. M., Price, D. C., Papahadjopoulos, D. 1988 An improved method for in vivo tracing and imaging of liposomes using a gallium-67-deferoxamine complex. J Liposome Res 1:123-135.
94. Ogihara-Umeda, I., Sasaki, T., Nishigori, H. 1992. Development of a liposome-encapsulated radionuclide with preferential tumor accumulation-the choice of radionuclide and chelating ligand. Nucl Med Biol 19:753-757.
95. Phillips, W. T., Rudolph, A. S., Goins, B., Timmons, J. H., Klipper, R., Blumhardt, R. 1992. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Nucl Med Biol 19:539-547.
96. Hnatowich, D. J., Friedman, B., Clancy, B., Novak, M. 1981. Labeling of preformed liposomes with Ga-67 and Tc-99m by chelation. J Nucl Med 22:810-814.
97. Goto, R., Kubo, H., Okada, S. 1989. Liposomes prepared from synthetic amphiphiles. I. Their technetium labeling and stability. Chem Pharm Bull Tokyo 37: 1351-1354.
98. 99mTc to lipid vesicles containing the lipophilic chelate dipalmitoylphosphatidylethanolamine-DTPA. Nucl Med Biol 19:831-840.
99. 99mTc by the hydrazino nicotinyl derivative. J Nucl Med 40:192-197.
100. Torchilin, V.P. 1996. Liposomes as delivery agents for medical imaging. Mol Med Today 2:242-249.
101. Laverman, P., Boerman, O.C., Oyen, J.G., Dams, E.T.M., Storm, G., Corstens, F.H.M. 1999. Liposomes for scintigraphic detection of infection and inflamation. Adv Drug Deliv Rev 37:225-235.
102. Oku, N., Tokudome, Y., Tsukada, H., Okada, S. 1995. Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. Biochim Biophys Acta 1238:85-90.
103. Oku, N., Tokudome, Y., Tsukada, H., Kosugi, T., Namba, Y., Okada, S. 1996. In vivo trafficking of long-circulating liposomes in tumor-bearing mice determined by positron emission tomography. Biopharm Drug Dispos 17:435-441.
104. Hafeli, U., Tiefenauer, L.X., Schubiger, P.A., Weder, H.G. 1991. A lipophilic complex with 186Re/188Re incorporated in liposomes suitable for radiotherapy. Nucl Med Biol 18:449-454.
105. Utkhede, D., Yeh, V., Szucs, M., Tilcock, C. 1994. Uptake of yttrium-90 into lipid vesicles. J Liposome Res 4(2):1049-1061.
106. Kostarelos, K. Emfietzoglou, D., Stamatelou, M. 1999. Liposome-mediated delivery of radionuclides to tumor models for cancer radiotherapy: a quantitative analysis. J Liposome Res 9(3):407-424.
107. Attix, F. H. Introduction to radiological physics and radiation dosimetry. Wiley, New York, 1986.
108. Strand, S-E, Jonsson, B-A, Ljungberg, M., Tennvall, J. 1993. Radioimmunotherapy dosimetry-a review. Acta Oncol 32:807-817.
109. Mattson, S., Johansson, L. 1999. Medical internal dosimetry: where are we going? Proc 6th Int Radiopharm Dosim Symp, Stelson, A., Stably, M. G. (Eds), Oak Ridge Associated Universities, Oak Ridge, TN, pp. 1-12.
110. Bardies, M., Myers, M. J. 1996. Computational methods in radionuclide dosimetry. Phys Med Biol 41:1941-1955.
111. Marinelli, L. D. 1942. Dosage determination with radioactive isotopes. Am J Roentgenol Radium Therapy. 47:210-216.
112. Stelson, A. T. S., Watson, E. E., Cloutier, R. J. 1995. A history of medical internal dosimetry. Health Phys 69:766-782.
113. Loevinger, R., Budinger, T. F., Watson, E. E. MIRD primer for absorbed dose calculations. The Society of Nuclear Medicine, New York, 1991.
114. Watson, E. E., Stabin, M. G. 1993. MIRD formulation. Med Phys 20:511-514.
115. Weber, D. A., Eckerman, K. F., Dillman, L. T., Ryman, J. C. MIRD radionuclide data and decay scheme. The Society of Nuclear Medicine, New York, 1989
116. Cloutier, R. J., Watson, E. E., Rohrer, R. H., Smith, E. M. 1973. Calculating the radiation dose to an organ. J Nucl Med 14:53-55.
117. Coffey, J. L., Watson, E.E. 1979. Calculating dose from remaining body activity: a comparison of two methods. Med Phys 6:307-308.
118. Snyder, W. S., Ford, M. R., Warner, G. G., Watson, S. B. MIRD Pamphlet 11: "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. The Society of Nuclear Medicine, New York, 1975.
119. Stabin, M. G. 1996. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538-546.
120. Strand, S-E., Zanzonico, P., Johnson, T. K. 1993. Pharmacokinetic modeling. Med Phys 20:515-527.
121. Roedler, H.D. 1981. Accuracy of internal dose calculations with special consideration of radiopharmaceutical biokinetics. Proc 3rd Int Radiopharm Dosim Symp, Wetson, E. E., Stelson, A. T., Coffey, J. L., Cloutier, R. J. (Eds), Oak Ridge Assoc. Univ., Oak Ridge, TN, pp. 1-20.
122. Yates, F. E., Kugler, P. N. 1986. Similarity principles and intrinsic geometries: contrasting approaches to interspecies scaling. J Pharmac Sci 75:1019-1027.
123. Sparks, R. B., Aydogan, B. 1999. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Proc 6th Int Radiopharm Dosim Symp, Stelson, A., Stably, M. G. (Eds), Oak Ridge Associated Universities, Oak Ridge, TN, pp. 705-716.
124. Johnson, T. K., McClure, D. L., McCourt, S. L., Andl, G. J., Berman, B. D., Koss, J., Newman, F. D. 1999. MABDOSE: A computer program for the calculation of dose. Proc 6th Int Radiopharm Dosim Symp, Stelson, A., Stably, M. G. (Eds), Oak Ridge Associated Universities, Oak Ridge, TN, pp. 425-439.
125. Tagesson, M., Ljungberg, M., Strand, S-E. 1999. The SIMDOS Monte Carlo code for the conversion of activity distributions to absorbed dose and dose-rate distributions. Proc 6th Int Radiopharm Dosim Symp, Stelson, A., Stably, M. G. (Eds), Oak Ridge Associated Universities, Oak Ridge, TN, pp. 416-424.
126. Meredith, R. F., Johnson, T. K., Plott, G., Macey, D. J., Vessella, R. L., Wilson, L. A., Breitz, H. B., Williams, L. E. 1993. Dosimetry of solid tumors. Med Phys 20:583-592.
127. Sgouros, G. 1999. Treatment planning for internal emitter therapy: methods, applications, and clinical implications. Proc 6th Int Radiopharm Dosim Symp, Stelson, A., Stably, M. G. (Eds), Oak Ridge Associated Universities, Oak Ridge, TN, pp. 13-25.
128. Ellett, W. H., Humes, R. M. 1971. MIRD Pamphlet 8: absorbed fractions for small volumes containing photon-emitting radioactivity. J Nucl Med 12(suppl):25-32.
129. Siegel, J. A., Stabin, M. G. 1994. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med 35:152-156.
130. Goddu, S. M., Howell, R. W., Rao, D. V. 1994. Cellular dosimetry: absorbed for monoenergetic electron and alpha particle sources and S values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 35:303-316.
131. Goddu, S. M., Rao, D. V., Howell, R. W. 1994. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 35: 521-530.
132. Howell, R. W. 1994. The MIRD schema: from organ to cellular dimensions. J Nucl Med 35:531-533.
133. Makrigiorgos, G.M., Adelstein, S.J., Kassis, A. I. 1989. Limitations of conventional internal dosimetry at the cellular level. J Nucl Med 30:1856-1864.
134. Makrigiorgos, G.M., Adelstein, S.J., Kassis, A.I. 1990. Cellular radiation dosimetry and its implications for estimation of radiation risks. Illustrative results with technitium-99m-labeled microspheres and macroaggregates. JAMA 264:592-595.
135. Makrigiorgos, M.G., Baranowska-Kortylewicz, J., Van den Abbeele, A. D. 1990. Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: dosimetry at the cellular level and comparison with conventional dosimetry. Radiat Prot Dosim 31:319-324.
136. Makrigiorgos, M.G., Ito, S., Baranowska-Kortylewicz, J., Vinter, D.W., Iqbal, A., Van den Abbeele, A.D., Adelstein, S.J., Kassis, A.I. 1990. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications. J Nucl Med 31:1358-1363.
137. Kwok, C.S., Prestwitch, W.V., Wilson, B.C. 1985. Calculation of radiation doses for nonuniformly distributed b and g radionuclides in soft tissue. Med Phys 12: 405-414.
138. Humm, J.L. 1986. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27:1490-1497.
139. Kassis, A.I. 1992. The MIRD approach: remembering the limitations. J Nucl Med 33:781-782.
140. Howell, R. W., Rao, D. V., Sastry K. S. R. 1989. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med Phys 16: 66-74.
141. Leichner, P. K., Kwok, C. K. 1993. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles. Med Phys 20:529-534.
142. Loevinger, R., Japha, E. M., Brownell, G. L. 1956. Discrete radioisotopes sources. In: Radiation Dosimetry, Academic, New York, 693-799.
143. Berger, M. J. 1968. Energy deposition in water by photons from point isotropic sources. J Nucl Med 9(suppl):15-25.
144. Berger, M. J. MIRD Pamphlet 7: Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. The Society of Nuclear Medicine, New York, New York, 1971.
145. Werner, B. L. 1987. Dose distributions in regions containing beta sources: small scale nonuniformities. Med Phys 14:807-808.
146. Werner, B. L., Kwok, C. S., Das, I. J. 1988. Dose distributions in regions containing beta sources: large spherical regions in a homogeneous medium. Med Phys 15: 358-363.
147. Werner, B. L., Kwok, C. S., Das, I. J. 1991. Dose distributions in regions containing beta sources: uniform spherical source regions in homogeneous media. Med Phys 18:1181-1191.
148. Leichner, P. K. 1994. A unified approach to photon and beta particle dosimetry. J Nucl Med 35:1721-1729.
149. Sgouros, G., Barest, G., Thekkumthala, J., Chui, C., Mohan, R., Bigler, R. E., Zanzonico, P. B. 1990. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 31: 1884-1891.
150. Sgouros, G., Chiu, S., Pentlow, K. S., Brewster, L. J., Kalaigian, H., Baldwin, B., Daghighian, F., Graham, M. C., Larson, S. M., Mohan, R. 1993. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 34:1595-1601.
151. Andreo, P. 1991. Monte Carlo techniques in medical radiation physics. Phys Med Biol 36:861-920.
152. Furhang, E.E., Chui, C.S., Kolbert, K.S., Larson, S.M., Sgouros, G. 1997. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys 24:1163-1172.
153. Erdi, A.K., Erdi, Y.E., Yorke, E.D., Wessels, B.W. 1996. Treatment planning for radio-immunotherapy. Phys Med Biol 41:2009-2026.
154. Rossi, H.H., Zaider, M. Microdosimetry and its applications. Springer, Berlin, 1996.
155. Humm, J.L., Roeske, J.C., Fisher, D.R., Chen, G.T.Y. 1993. Microdosimetric concepts in radioimmunotherapy. Med Phys 20:535-541.
156. Humm, J.L. 1999. Current status of cellular dosimetry. Proc 6th Int Radiopharm Dosim Symp, Stelson, A., Stably, M. G. (Eds), Oak Ridge Associated Universities, Oak Ridge, TN, pp. 172-187.
157. Hawthorne, M.F. 1998. New horizons for therapy based on the boron neutron cap-ture reaction. Mol Med Today 4:174-181.
158. Nigg, D. 1999. Some recent trends and progress in the physics and biophysics of neutron capture therapy. Prog Nucl Energy 35:79-127.
159. Shih, J. A., Brugger, R. M. 1991. Gadolinium as a neutron capture therapy agent. Med Phys 19:733-744.
160. 157Gd(n,g) reactions for neutron capture therapy. Proc 6th Int Radiopharm Dosim Symp 336-344.
161. 7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiat Res 111:14-25.
162. Zamenhof, R. G. 1999. Microdosimetry for boron neutron capture therapy: a review. J Neuro-Oncology 33:81-91.
163. Yanagie, H., Tomita, T., Kobayashi, H. Fujii, Y., Takahashi, T., Hasumi, K., Nariuchi, H., Sekiguchi, M. 1991. Application of boronated anti-cea immunoliposomes to tumor-cell growth inhibition in in vitro boron neutron capture therapy model. Br J Cancer 63:522-526.
164. Shelly, K., Feakes, D.A., Hawthorne, M.F., Schmidt, P.G., Krisch, T.A., Bauer, W.F. 1992. Model studies directed toward the boron neutron capture therapy of cancer - boron delivery to murine tumors with liposomes. Proc Natl Acad Sci USA 89(19):9039-9043.
165. 3] -Synthesis and liposomal delivery to murine tumors. Proc Natl Acad Sci USA 91(8): 3029-3033.
166. Feakes, D.A., Shelly, K., Hawthorne, M.F. 1995. Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc Natl Acad Sci USA 92(5):1367-1370.
167. Mehta, S.C., Lai, J.C.K., Lu, D.R. 1996. Liposomal formulations containing sodium mercaptoundecahydrododecaborate (BSH) for boron neutron-capture therapy. J Microencap 13(3):269-279.
168. Yanagie, H., Tomita, T., Kobayashi, H., Fujii, Y., Nonaka, Y., Saegusa, Y., Hasumi, K., Eriguchi, M., Kobayashi, T., Ono, K. 1997. Inhibition of human pancreatic cancer growth in nude mice by boron neutron capture therapy. Br J Cancer 75:660-665.
169. Watson-Clark R.A., Banquerigo, M.L., Shelly, K., Hawthorne, M.F., Brahn, E. 1998. Model studies directed toward the application of boron neutron capture therapy to rheumatoid arthritis: boron delivery by liposomes in rat collagen-induced arthritis. Proc Natl Acad Sci USA 95(5):2531-2534.
170. Hawthorne, M.F., Shelly, K. 1997. Liposomes as drug delivery vehicles for boron agents. J Neuro-Oncol 33:53-58.
171. Nakagawa, Y., Hatanaka, H. 1997. Boron neutron capture therapy. J Neuro-Oncol 33:141-152.
172. Barth, R.F., Soloway, A.H., Fairchild, R.G., Brugger, R.M. 1996. Boron neutron capture therapy for cancer: realities and prospects. Cancer 70:2995-3007.
173. Hawthorne, M.F. 1993. The role of chemistry in the development of boron neutron capture therapy for cancer. Angew Chem Int Ed Engl 32:950-984.
174. 8] as a potential agent for boron neutron capture therapy. Proc Natl Acad Sci USA 96(11):6406-6410.
175. Johnsson, M., Bergstrand, N., Edwards, K. 1999. Optimization of drug loading procedures and characterization of liposomal formulations of two novel agents intended for boron neutron capture therapy (BNCT). J Liposome Res 9(1):53-79.
176. Griffin, B.R., Laramore, G.E. 1997. Boron neutron capture therapy enhancement of fast neutron therapy. US Patent 5,630,786.
177. Wessels, B.W., Rogus, R.D. 1984. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11:638-645.
178. Howell, R.W., Goddu, S.M., Rao, D.V. 1994. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of long-lived radionuclides. J Nucl Med 35:1861-1869.
179. Langmuir, V.K., Fowler, J.F., Knox, S.J., Wessels, B.W., Sutherland, R.M., Wong, J.Y. 1993. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 20:601-610.
180. Emfietzoglou, D., Kostarelos, K., Stamatelou, M. 1999. Liposome delivery of particle-emitting radionuclides for tumor radiotherapy. Proc Int Symp Control Rel Bioact Mat 26:505-506.
181. O'Donoghue, J.A., Wheldon, T.E. 1996. Targeted therapy using Auger-electron emitters. Phys Med Biol 41:1973-1992.
182. McDevitt, M.R., Sgouros, G., Finn, R.D., Humm, J.L., Jurcic, J.G., Larson, S.M., Scheinberg, D.A. 1998. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25:1341-1351.
183. Roeske, J.C., Stinchcomb, T.G. 1997. Dosimetric framework for therapeutic alpha-particle emitters. J Nucl Med 38:1923-1929.
184. Yuan, F., Leunig, M., Huang, S.K., Berk, D.A., Papahadjopoulos, D., Jain, R. K. 1994. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356.
185. Huang, S.K., Martin, F.J., Jay, G., Vogel, J., Papahadjopoulos, D., Friend, D.S. 1993. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathof 143:10-14.
186. Wu, N.Z., Da, D., Rudoll, T.L., Needham, D., Whorton, A.R., Dewhirst, M.W. 1993. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res 53:3765-3770.
187. Vaage, J., Donovan, D., Working, P., Uster, P. 1998. Cellular distribution of DOXIL® within selected tissues, assessed by confocal laser scanning microscopy. In: Lasic, D.D. and Papahadjopoulos, D. (eds) Medical applications of liposomes. Elsevier Science, Amsterdam, pp. 275-282.
188. O'Donoghue, J.A. 1999. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 40(8):1337-1341.